Multiple Sclerosis Trials in nice, france
Conditions / Multiple Sclerosis / nice, france
55 total trials for this combination
Showing top 10 of 55 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03232073 | Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis | COMPLETED | PHASE3 |
| NCT05269004 | A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06141473 | Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | RECRUITING | PHASE3 |
| NCT03599245 | This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS) | COMPLETED | PHASE3 |
| NCT06141486 | Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis | RECRUITING | PHASE3 |
| NCT00185211 | BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study | COMPLETED | PHASE3 |
| NCT02425644 | Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis | COMPLETED | PHASE3 |
| NCT00622700 | Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis | COMPLETED | PHASE3 |
| NCT00751881 | An Efficacy Study of Teriflunomide in Participants With Relapsing Multiple Sclerosis | COMPLETED | PHASE3 |
| NCT00803049 | Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE3 |